Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study.
about
Anticholinergic medication use and dementia: latest evidence and clinical implicationsMirabegron in overactive bladder patients: efficacy review and update on drug safetyAssessment of cognitive safety in clinical drug developmentAnticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic reviewCumulative use of strong anticholinergics and incident dementia: a prospective cohort studyDrugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysisAntidepressant use and cognitive decline in community-dwelling elderly people - The Three-City CohortCUA guideline on adult overactive bladderTurning over the rocks: role of anticholinergics and benzodiazepines in cognitive decline and falls.The potential applications of Apolipoprotein E in personalized medicineAn update on the diagnosis and management of dementing conditionsUse of anticholinergics and the risk of cognitive impairment in an African American populationDesigning prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors.Caffeine, cognitive functioning, and white matter lesions in the elderly: establishing causality from epidemiological evidence.Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review.Agitation and Irritability in Alzheimer's Disease: Evidenced-Based Treatments and the Black-Box Warning.Methodological challenges in determining longitudinal associations between anticholinergic drug use and incident cognitive decline.Cognitive decline in older persons initiating anticholinergic medications.Donepezil plus estradiol treatment enhances learning and delay-dependent memory performance by young ovariectomized rats with partial loss of septal cholinergic neuronsMedication management for people with dementia in primary care: description of implementation in the DelpHi study.Treating overactive bladder in the elderly.Anticholinergic drugs and their effects on delirium and mortality in the elderly.Use of CNS medications and cognitive decline in the aged: a longitudinal population-based studyDrug-induced cerebral glucose metabolism resembling Alzheimer's Disease: a case study.Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease.The greater sensitivity of elderly APOE ε4 carriers to anticholinergic medications is independent of cerebrovascular disease riskAntidepressant Use and Cognitive Decline: The Health and Retirement StudyLong-term anticholinergic use and the aging brain.Use of Medicines with Anticholinergic and Sedative Effect Before and After Initiation of Anti-Dementia Medications.How Prolific is Psychotropic Medicines Use in People with Dementia in Australia Within the Community Setting? A Retrospective Analysis.An Update on Geriatric Medication Safety and Challenges Specific to the Care of Older Adults.Lipid lowering agents, cognitive decline, and dementia: the three-city study.Managing polypharmacy in a 77-year-old woman with multiple prescribers.Sleep disturbances and driving practices of older drivers.Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older AdultsOver-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults.Polypharmacy and inappropriate medication use in patients with dementia: an underresearched problem.Long-term cognitive and functional effects of potentially inappropriate medications in older women.Falls risk reduction and treatment of overactive bladder symptoms with antimuscarinic agents: a scoping review.Drugs with anticholinergic properties: a current perspective on use and safety.
P2860
Q28068339-AC310693-0214-4023-82DB-873870362727Q28072230-8D6AF1F1-7B22-4A52-9796-6AC7F5C0E849Q28084637-774AC21E-4841-4440-98B1-7449FFA83954Q28085414-3804AD60-A75D-4A06-AE4B-238E002F9DF7Q28255929-AEBFBB24-5F60-412D-BBF3-F90C8A8A72BCQ28258219-9C69F66E-DF13-4A37-A711-E00225B748C5Q33582388-70DA8558-8CF6-4217-8D1F-B88509C05BB3Q33665026-405650D2-C128-43FD-9A33-73F1A17D416BQ33715169-A56BDDA4-E23B-4C82-B01E-D78E6C92A4C3Q33858831-8505F9D4-CC7B-45F3-A153-68328E225BCAQ33896147-42491A43-52B8-48A1-974A-2263E38C67FFQ34002967-4E1896C9-10DA-4A37-8217-303113257412Q34047968-FB317A24-4886-48F7-A0DF-57B98BDBAE6EQ34088937-2757D36A-D2B3-4CED-837E-8188D9EF1EB8Q34429787-B1AA3F78-5E42-4B04-AD06-DBBC22181393Q34506252-7C1840B6-95C9-468E-8DBD-9F8C579C1096Q34521956-08B83BFC-F89D-469E-9A97-A787AE5F4822Q34760402-89F4011C-2967-4ACA-A999-AAA8A30246D1Q34842990-E8BA4B55-4E11-4954-A80C-FF417FD4ACB4Q35041890-2897DFD8-E04B-4DD1-B02E-8B6C186C9B00Q35347702-640EC0AB-E3DC-42BB-ABB9-68E56ACF4B8CQ35428172-9EF9E186-1D21-432E-B4AE-9C999C2807F7Q35580037-2B3F3E80-28E0-474C-807D-FAAE62147868Q35688580-A80E0A5A-5ABC-4E3A-8876-C8BDB633DAA9Q35944999-EEEEE94B-AF13-4E42-BF95-1BBD37B5A62AQ36007813-E1EF4572-D6BE-4754-8F0A-C2F61B4CBFC2Q36201714-1A4CFBCD-DF64-47BB-81A3-A82BB665B1A7Q36906645-103F6EEF-FD57-4950-AA28-C12798D2F422Q36942845-D7D8BFB5-EDF9-48AB-B9D6-41D9C2D6FE21Q36942933-32A117B6-B46E-4A64-911B-40C13029CF07Q37025156-BD067DEF-C111-492D-B035-9C564B248D23Q37095998-1198B8D6-971C-443A-BE38-91564713F830Q37207700-3CEB7B28-4209-4760-9E3E-4BB126D2E9EAQ37230913-1727144C-28EB-4824-A0C4-3F969482D249Q37268405-E7D7657B-328A-439B-A599-66842870A9BCQ37446075-E9B4DF07-1FE9-43DC-8EB9-089E1DFA3CE4Q37632244-3A824124-5B1D-4955-9E5F-204A71E63DE8Q37670854-1F6DDD4C-9B51-4DD9-93B3-46C9D2393AF1Q37831263-1849887D-C52D-432E-9514-3B8027C0EAE5Q37884068-2E6EF210-5F35-4AAE-9532-53AF887E13FB
P2860
Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Drugs with anticholinergic pro ...... population: the 3-city study.
@ast
Drugs with anticholinergic pro ...... population: the 3-city study.
@en
Drugs with anticholinergic pro ...... population: the 3-city study.
@nl
type
label
Drugs with anticholinergic pro ...... population: the 3-city study.
@ast
Drugs with anticholinergic pro ...... population: the 3-city study.
@en
Drugs with anticholinergic pro ...... population: the 3-city study.
@nl
prefLabel
Drugs with anticholinergic pro ...... population: the 3-city study.
@ast
Drugs with anticholinergic pro ...... population: the 3-city study.
@en
Drugs with anticholinergic pro ...... population: the 3-city study.
@nl
P2093
P2860
P1476
Drugs with anticholinergic pro ...... l population: the 3-city study
@en
P2093
Annie Fourrier-Reglat
Isabelle Carrière
Jean-François Dartigues
Karen Ritchie
Olivier Rouaud
P2860
P304
P356
10.1001/ARCHINTERNMED.2009.229
P407
P577
2009-07-01T00:00:00Z